evidence table
Magnesium Glycinate Sleep Randomized Trial Evidence Table
Structured evidence table for Magnesium Glycinate Sleep Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Magnesium Glycinate Sleep Randomized Trial | Temporomandibular disorders (TMDs) are among the most common causes of chronic orofacial pain, with myalgia of the masticatory muscles being a major.Patients frequently present with persistent aching pain, muscle tenderness, and restricted jaw function, all of which significantly impair quality of life.While existing treatments are mainly symptomatic,emerging evidence suggests a role for electrolyte modulation. | 1 | Patil Shankargouda (2026) | The Role of Electrolytes in Muscle Pain Syndromes: A Systematic Review and Meta-Analysis With Implications for Temporomandibular Disorder |
| Magnesium Glycinate Sleep Randomized Trial | Notably, a recent randomized controlled trial demonstrated that local magnesium sulphate injection into the masseter muscle significantly reduced pain intensity and improved function in TMD myalgia, providing a direct clinical link between electrolyte biology and orofacial pain.This observation highlights the potential for broader exploration of electrolyte-based interventions in TMD. | 1 | Patil Shankargouda (2026) | The Role of Electrolytes in Muscle Pain Syndromes: A Systematic Review and Meta-Analysis With Implications for Temporomandibular Disorder |
| Magnesium Glycinate Sleep Randomized Trial | Muscle cramps – whether idiopathic nocturnal, pregnancy-associated, or exercise-induced – arise from abnormal neuromuscular excitability,impaired ion-channel regulation,and nociceptor sensitization.These same processes are also implicated in TMD myalgia,suggesting that insights from cramp interventions may inform novel strategies for managing orofacial muscle pain. | 1 | Patil Shankargouda (2026) | The Role of Electrolytes in Muscle Pain Syndromes: A Systematic Review and Meta-Analysis With Implications for Temporomandibular Disorder |
| Magnesium Glycinate Sleep Randomized Trial | This case series presents outcomes of the first 51 patients who participated in one such program and aims to add to preliminary evidence regarding the efficacy of a personalized multimodal integrative functional medicine approach to cognitive decline in the context of prior uncontrolled and ongoing controlled trials. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
| Magnesium Glycinate Sleep Randomized Trial | Management of vascular risk factors (hypertension, hyperlipidemia, diabetes), tobacco and alcohol counseling, and hearing evaluation were conducted through participants’ primary clinicians, consistent with standard dementia prevention guidelines. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
| Magnesium Glycinate Sleep Randomized Trial | As shown in, participants in the “improved” group were older and more likely to carry at least one APOE4 allele, whereas those in the “progressed” group were younger and started with lower baseline MoCA scores. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
| Magnesium Glycinate Sleep Randomized Trial | 1 5 - 1 5 - Alzheimer’s disease (AD) and related dementias are significant public health challenges with limited treatment options. | 4 | Kogan Mikhail (2026) | The Integrative Personalized Functional Medicine Approach to Reverse Cognitive Decline: Academic Experience of the First 51 Patients Case Series |
Source documents